IL141507A0 - Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas - Google Patents

Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas

Info

Publication number: IL141507A0
Authority: IL; Israel
Prior art keywords: microadenomas; adhd; parkinson; disease; treatment
Prior art date: 1998-09-21

Application number

IL14150799A

Other languages

English (en)

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-21

Filing date

1999-09-03

Publication date

2002-03-10

1999-09-03 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2002-03-10 Publication of IL141507A0 publication Critical patent/IL141507A0/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL14150799A 1998-09-21 1999-09-03 Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas IL141507A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10119198P	1998-09-21	1998-09-21
US10386898P	1998-10-12	1998-10-12
PCT/IB1999/001503 WO2000016777A1 (en)	1998-09-21	1999-09-03	Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas

Publications (1)

Publication Number	Publication Date
IL141507A0 true IL141507A0 (en)	2002-03-10

Family

ID=26798000

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL14150799A IL141507A0 (en)	1998-09-21	1999-09-03	Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
IL16483999A IL164839A0 (en)	1998-09-21	1999-09-03	Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL16483999A IL164839A0 (en)	1998-09-21	1999-09-03	Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas

Country Status (38)

Country	Link
US (2)	US6300329B1 (et)
EP (1)	EP1115402A1 (et)
JP (1)	JP2002526448A (et)
KR (3)	KR20030088512A (et)
CN (1)	CN1319013A (et)
AP (1)	AP1456A (et)
AR (1)	AR029739A1 (et)
AU (1)	AU760230B2 (et)
BG (1)	BG105445A (et)
BR (1)	BR9913975A (et)
CA (1)	CA2344670A1 (et)
CO (1)	CO5140075A1 (et)
CZ (1)	CZ20011006A3 (et)
DZ (1)	DZ2894A1 (et)
EA (2)	EA200301063A1 (et)
EE (1)	EE200100179A (et)
GE (1)	GEP20033081B (et)
GT (1)	GT199900154A (et)
HN (1)	HN1999000146A (et)
HR (1)	HRP20010209A2 (et)
HU (1)	HUP0103691A3 (et)
ID (1)	ID28028A (et)
IL (2)	IL141507A0 (et)
IS (1)	IS5852A (et)
MA (1)	MA26690A1 (et)
MY (1)	MY127939A (et)
NO (1)	NO20011409L (et)
NZ (1)	NZ509855A (et)
OA (1)	OA11653A (et)
PA (1)	PA8482001A1 (et)
PE (1)	PE20001084A1 (et)
PL (1)	PL346904A1 (et)
SK (1)	SK3592001A3 (et)
TN (1)	TNSN99177A1 (et)
TR (2)	TR200402083T2 (et)
TW (1)	TW518225B (et)
WO (1)	WO2000016777A1 (et)
YU (1)	YU21701A (et)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HN1999000146A (es) *	1998-09-21	2000-11-11	Pfizer Prod Inc	Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
ES2425114T3 (es) *	2000-03-16	2013-10-11	The Mclean Hospital Corporation	CDP-colina y uridina para el tratamiento del abuso del acohol
GB0027020D0 (en) *	2000-11-03	2000-12-20	Univ Manchester	Treatment of movement disorders
US7053092B2 (en)	2001-01-29	2006-05-30	Otsuka Pharmaceutical Co., Ltd.	5-HT1a receptor subtype agonist
AU2002315336A1 (en) *	2001-06-18	2003-01-02	Psychiatric Genomics, Inc.	Method for neural stem cell differentiation using 5ht-1a agonists
US20030036555A1 (en) *	2001-08-03	2003-02-20	Boehringer Ingelheim Pharma Kg	Pramipexole for the treatment of ADHD
AR033485A1 (es)	2001-09-25	2003-12-26	Otsuka Pharma Co Ltd	Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
EP1765075A4 (en) *	2004-06-10	2010-11-10	Mclean Hospital Corp	PYRIMIDINES, AS FORM. uridine; IN THE TREATMENT OF PATIENTS WITH MANIC-DEPRESSIVE PSYCHOSIS
WO2006020703A1 (en) *	2004-08-11	2006-02-23	The Mclean Hospital Corporation	Compounds for the treatment of marihuana dependence, withdrawal, and usage
MY148644A (en)	2005-07-18	2013-05-15	Orion Corp	New pharmaceutical compounds
GT200600416A (es)	2005-09-12	2007-09-20		Sales salicilato y gentisato de un compuesto de piperazina
PE20070523A1 (es)	2005-09-12	2007-06-28	Wyeth Corp	Formulacion de liberacion sostenida del glucuronato de (8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona
GT200600414A (es)	2005-09-12	2007-09-20		Sal de glucuranato de compuesto de piperazine
US9066903B2 (en) *	2006-02-28	2015-06-30	The United States Of America As Represented By The Department Of Veterans Affairs	Pharmacological treatment of Parkinson's disease
US20080131492A1 (en) *	2006-06-23	2008-06-05	Spherics, Inc.	Dosage forms for movement disorder treatment
WO2008083442A1 (en) *	2007-01-10	2008-07-17	Brc Operations Pty Limited	Method for formulating combination medications for adhd
CN101318020B (zh) *	2007-06-06	2011-09-28	四川科瑞德制药有限公司	抗焦虑或/和抗抑郁的药物组合物及用途
US20100041621A1 (en) *	2008-08-15	2010-02-18	Perry Renshaw	Methods and compositions for improving cognitive performance
GB201112987D0 (en)	2011-07-28	2011-09-14	Ge Healthcare Ltd	Novel compound
HK1215170A1 (zh)	2012-11-14	2016-08-19	The Johns Hopkins University	治療精神分裂症的方法和組合物
WO2014172372A1 (en)	2013-04-15	2014-10-23	Northwestern University	Treatment for dopaminergic disorders
CN104892589A (zh)	2014-03-07	2015-09-09	中国科学院上海药物研究所	一类杂环化合物、其制备方法和用途
WO2016186968A1 (en)	2015-05-15	2016-11-24	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Compositions and methods for treating motor disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1990008148A1 (en) *	1989-01-23	1990-07-26	Pfizer Inc.	Bis-aza-bicyclic anxiolytic agents
WO1992000075A1 (en) *	1990-06-29	1992-01-09	Pfizer Inc.	Pyridopyrazine derivatives for treating substance abuse and addiction
US5281607B1 (en) *	1992-10-08	1998-05-19	Univ New York	Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
GB9408084D0 (en) *	1994-04-23	1994-06-15	Boots Co Plc	Medical treatment
EP0765320B1 (en) *	1994-06-14	2001-10-10	Pfizer Inc.	Benzimidazolone derivatives with central dopaminergic activity
US5877183A (en) *	1996-06-06	1999-03-02	Ergo Research Corporation	Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
HN1999000146A (es) *	1998-09-21	2000-11-11	Pfizer Prod Inc	Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.

1999
- 1999-08-27 HN HN1999000146A patent/HN1999000146A/es unknown
- 1999-09-03 EA EA200301063A patent/EA200301063A1/ru unknown
- 1999-09-03 ID IDW20010637A patent/ID28028A/id unknown
- 1999-09-03 WO PCT/IB1999/001503 patent/WO2000016777A1/en not_active Ceased
- 1999-09-03 EP EP99939567A patent/EP1115402A1/en not_active Withdrawn
- 1999-09-03 CA CA002344670A patent/CA2344670A1/en not_active Abandoned
- 1999-09-03 HU HU0103691A patent/HUP0103691A3/hu unknown
- 1999-09-03 HR HR20010209A patent/HRP20010209A2/hr not_active Application Discontinuation
- 1999-09-03 BR BR9913975-8A patent/BR9913975A/pt not_active IP Right Cessation
- 1999-09-03 KR KR10-2003-7014169A patent/KR20030088512A/ko not_active Ceased
- 1999-09-03 KR KR10-2004-7006381A patent/KR20040054752A/ko not_active Ceased
- 1999-09-03 PL PL99346904A patent/PL346904A1/xx unknown
- 1999-09-03 NZ NZ509855A patent/NZ509855A/xx unknown
- 1999-09-03 CN CN99811132A patent/CN1319013A/zh active Pending
- 1999-09-03 SK SK359-2001A patent/SK3592001A3/sk unknown
- 1999-09-03 IL IL14150799A patent/IL141507A0/xx unknown
- 1999-09-03 TR TR2004/02083T patent/TR200402083T2/xx unknown
- 1999-09-03 EA EA200100204A patent/EA200100204A1/ru unknown
- 1999-09-03 OA OA1200100068A patent/OA11653A/en unknown
- 1999-09-03 KR KR10-2001-7003552A patent/KR100468340B1/ko not_active Expired - Fee Related
- 1999-09-03 AU AU53831/99A patent/AU760230B2/en not_active Ceased
- 1999-09-03 EE EEP200100179A patent/EE200100179A/et unknown
- 1999-09-03 YU YU21701A patent/YU21701A/sh unknown
- 1999-09-03 JP JP2000573738A patent/JP2002526448A/ja active Pending
- 1999-09-03 TR TR2001/01357T patent/TR200101357T2/xx unknown
- 1999-09-03 AP APAP/P/2001/002102A patent/AP1456A/en active
- 1999-09-03 GE GEAP19995812A patent/GEP20033081B/en unknown
- 1999-09-03 IL IL16483999A patent/IL164839A0/xx unknown
- 1999-09-03 CZ CZ20011006A patent/CZ20011006A3/cs unknown
- 1999-09-13 GT GT199900154A patent/GT199900154A/es unknown
- 1999-09-15 PA PA19998482001A patent/PA8482001A1/es unknown
- 1999-09-15 TW TW088115941A patent/TW518225B/zh not_active IP Right Cessation
- 1999-09-17 PE PE1999000948A patent/PE20001084A1/es not_active Application Discontinuation
- 1999-09-17 MY MYPI99004051A patent/MY127939A/en unknown
- 1999-09-17 AR ARP990104680A patent/AR029739A1/es unknown
- 1999-09-20 TN TNTNSN99177A patent/TNSN99177A1/fr unknown
- 1999-09-20 MA MA25774A patent/MA26690A1/fr unknown
- 1999-09-20 DZ DZ990194A patent/DZ2894A1/xx active
- 1999-09-21 US US09/400,659 patent/US6300329B1/en not_active Expired - Fee Related
- 1999-09-21 CO CO99059863A patent/CO5140075A1/es unknown
2001
- 2001-02-20 IS IS5852A patent/IS5852A/is unknown
- 2001-03-20 NO NO20011409A patent/NO20011409L/no not_active Application Discontinuation
- 2001-04-13 BG BG105445A patent/BG105445A/xx unknown
- 2001-05-03 US US09/848,068 patent/US6608064B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
GT199900154A (es)	2001-03-06
IL164839A0 (en)	2005-12-18
AU5383199A (en)	2000-04-10
NO20011409D0 (no)	2001-03-20
OA11653A (en)	2004-12-08
KR100468340B1 (ko)	2005-01-27
HUP0103691A3 (en)	2003-01-28
ID28028A (id)	2001-05-03
EE200100179A (et)	2002-10-15
CA2344670A1 (en)	2000-03-30
KR20030088512A (ko)	2003-11-19
AR029739A1 (es)	2003-07-16
BR9913975A (pt)	2001-06-19
HUP0103691A2 (hu)	2002-02-28
KR20010075222A (ko)	2001-08-09
SK3592001A3 (en)	2001-12-03
NO20011409L (no)	2001-03-28
GEP20033081B (en)	2003-10-27
WO2000016777A1 (en)	2000-03-30
US6608064B2 (en)	2003-08-19
CZ20011006A3 (cs)	2001-09-12
JP2002526448A (ja)	2002-08-20
CN1319013A (zh)	2001-10-24
EA200100204A1 (ru)	2001-08-27
MY127939A (en)	2007-01-31
AP1456A (en)	2005-09-30
US20010034347A1 (en)	2001-10-25
PL346904A1 (en)	2002-03-11
NZ509855A (en)	2003-04-29
HN1999000146A (es)	2000-11-11
PA8482001A1 (es)	2000-05-24
EA200301063A1 (ru)	2004-12-30
PE20001084A1 (es)	2000-10-18
YU21701A (sh)	2004-07-15
TNSN99177A1 (fr)	2005-11-10
CO5140075A1 (es)	2002-03-22
EP1115402A1 (en)	2001-07-18
HRP20010209A2 (en)	2002-04-30
TR200402083T2 (tr)	2004-10-21
BG105445A (en)	2001-12-29
TW518225B (en)	2003-01-21
TR200101357T2 (tr)	2001-08-21
AP2001002102A0 (en)	2001-03-31
MA26690A1 (fr)	2004-12-20
US6300329B1 (en)	2001-10-09
DZ2894A1 (fr)	2003-12-15
IS5852A (is)	2001-02-20
KR20040054752A (ko)	2004-06-25
AU760230B2 (en)	2003-05-08

Publication	Publication Date	Title
IL164839A0 (en)	2005-12-18	Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
EP1043991A4 (en)	2005-02-02	TREATMENT OF ALZHEIMER DISEASE
GB2367060B (en)	2003-06-04	Alzheimer's disease secretase,app substrates therefor,and uses therefor
HUP0103856A3 (en)	2003-11-28	Pharmaceutical composition for the treatment of acute disorders
WO1999048482A3 (en)	2000-11-23	Smilagenin and anzurogenin-d for the treatment of alzheimer's disease
FI20000720L (fi)	2000-03-29	Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi
HUP0003852A3 (en)	2003-04-28	Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
HUP9900163A3 (en)	2001-10-29	Process for the preparation of sterol-and stanol-esters, and use thereof
IL119417A0 (en)	1997-01-10	Drug for Parkinson's disease
NZ513650A (en)	2001-09-28	Pharmaceutical composition for the treatment of urinary incontinence, motion sickness and vertigo
ZA962715B (en)	1997-10-06	Pharmaceutical agents for the treatment of Alzheimer's disease.
AU5550800A (en)	2001-01-09	Diagnosis and treatment of alzheimer's disease
GB0011410D0 (en)	2000-06-28	Therapeutic combination for treating Alzheimer's disease
AU1405899A (en)	1999-06-07	Treatment for alzheimer's disease
GB0011408D0 (en)	2000-06-28	Therapeutic combination for treating Alzheimer's Disease
HUP0105111A3 (en)	2003-02-28	2,5-substituted benzolsulfonylureas and thioureas, methods for the production thereof, use thereof and pharmaceutical preparations containing the same
AU2002215187A1 (en)	2002-04-29	S-adenosylmethionine and derivatives thereof for the treatment and prevention ofalzheimer's disease
AU2137595A (en)	1995-11-16	Use of arylpiperazine derivatives for the treatment of Parkinson's disease and psychosis
ZA200102029B (en)	2002-07-12	Pharmaceutical agents for the treatment of Parkinson's disease, ADHD and microadenomas.
HUP0103149A3 (en)	2003-03-28	Pharmaceutical composition for treatment of alzheimer's disease
GB9704174D0 (en)	1997-04-16	Agent for medical treatment
GB9922194D0 (en)	1999-11-17	Compounds for improved treatment of parkinson's disease
SI1007040T1 (en)	2002-10-31	Use of phanquinone for the treatment of alzheimer's disease
GB9828564D0 (en)	1999-02-17	Materials and methods for the treatment and diagnosis of cancer
GC0000176A (en)	2006-03-29	Pharmaceutical combination preparations for the treatment of cardiac disorders